Interrogation of liquid biopsies from patients [13–15] identified fibronectin (FN1) and S100A9 as potential markers of CRC progression, and proposed that the combination of S100A9 and tenascin-C with CEA is superior to CEA alone as a CRC biomarker. This evidence concerns the gene FN1 and colorectal carcinoma.